Dengue virus vaccine composition

Vaccine compositions that comprise at least one antigen based on the dengue virus (DV) capsid protein and the oligonucleotide identified as SEQ ID NO 1. The vaccine composition that comprises a fusion protein formed by the DV2 capsid and domain III of the envelope protein of the same serotype, toget...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Hermida Cruz, Lisset, Suzarte Portal, Edith, Guillen Nieto, Gerardo Enrique, Valdes Prado, Iris, Guzman Tirado, Maria Guadalupe, Gil Gonzalez, Lazaro, Izquierdo Oliva, Alienys, Lazo Vazquez, Laura, Garcia Arechavaleta, Angelica de la Caridad, Romero Fernandez, Yaremy, Marcos Lopez, Ernesto, Ramirez Bartutis, Rosa Liset, Perez, Guevara Olga Lidia, Alvarez Vera, Mayling, Perez Fuentes, Yusleidi de la Caridad, Castro Velazco, Jorge, Lopez Fernandez, Lazaro
Format: Patent
Sprache:eng
Schlagworte:
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Vaccine compositions that comprise at least one antigen based on the dengue virus (DV) capsid protein and the oligonucleotide identified as SEQ ID NO 1. The vaccine composition that comprises a fusion protein formed by the DV2 capsid and domain III of the envelope protein of the same serotype, together with the oligonucleotide identified as SEQ ID NO 1, gives rise to higher levels of cellular immune response and protection in mice as compared with that produced by formulations of the same antigen together with oligonucleotides with potential adjuvant capacity which were reported previously. The efficacy of the compositions that comprise the SEQ ID NO 1 oligonucleotide has been demonstrated in non-human primates. These compositions may be monovalent, bivalent or tetravalent and are combined in different immunization regimes with a view to inducing a functional immune response to the four viral serotypes.